Cb2 receptors blocks accumulation of human hepatic myofibroblasts: a novel antifibrogenic pathway in the liver

Abstract

Methods for treating diseases of the livers mediated by CB2 receptors are described. The methods may include administering an effective amount of a cannabinoid, an agent that activates a CB2 receptor, a composition that includes a non-selective agonist of CB2 and a selective antagonist of CB1, a composition that includes an agonist of CB2 receptors, and/or a composition that includes an up-regulator of CB2 receptors to a patient who has non-alcoholic steatohepatitis.

1 . A method of treating a disease of the liver, comprising administering an effective amount of a cannabinoid to a patient having the disease, wherein the disease is non-alcoholic steatohepatitis. 
     
     
         2 . A method of treating a disease of the liver, comprising administering an agent that activates a CB2 receptor to a patient having the disease, wherein the disease is non-alcoholic steatohepatitis. 
     
     
         3 . A method of treating a disease of the liver, comprising administering a composition comprising a non-selective agonist of CB2 and a selective antagonist of CB1 to a patient having the disease, wherein the disease is non-alcoholic steatohepatitis. 
     
     
         4 . A method of treating a disease of the liver, comprising administering a composition comprising an agonist of CB2 receptors to a patient having the disease, wherein the disease is non-alcoholic steatohepatitis. 
     
     
         5 . A method of treating a disease of the liver, comprising administering a composition comprising an up-regulator of CB2 receptors to a patient having the disease, wherein the disease is non-alcoholic steatohepatitis.